218 related articles for article (PubMed ID: 36225945)
1. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
[TBL] [Abstract][Full Text] [Related]
2. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit.
Wang Y; Wang T; Xie J; Yang Q; Zheng X; Dong W; Xing J; Wang X; Dong Y
Pharmacotherapy; 2016 Jul; 36(7):757-65. PubMed ID: 27284960
[TBL] [Abstract][Full Text] [Related]
4. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan.
Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y
Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723
[TBL] [Abstract][Full Text] [Related]
5. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
[TBL] [Abstract][Full Text] [Related]
6. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
[TBL] [Abstract][Full Text] [Related]
7. The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia.
Zhou PY; Lim TP; Tang SLS; Liew Y; Chua SGN; Lim LLC; Lee HLW; Tan SX; Lai OF; Tan TT; Wong GC; Kwa LHA
J Glob Antimicrob Resist; 2020 Jun; 21():427-433. PubMed ID: 31846723
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis.
Maertens JA; Rahav G; Lee DG; Haider S; Ramirez-Sanchez IC; Klimko N; Ponce-de-León A; Han S; Wrishko R; Winchell GA; Grandhi A; Waskin H;
Clin Drug Investig; 2023 Sep; 43(9):681-690. PubMed ID: 37676612
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring and
Chen X; Xiao Y; Li H; Huang Z; Gao J; Zhang X; Li Y; Van Timothee BM; Feng X
Transl Pediatr; 2022 Aug; 11(8):1311-1322. PubMed ID: 36072540
[TBL] [Abstract][Full Text] [Related]
10. Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole.
Teng GJ; Bai XR; Zhang L; Liu HJ; Nie XH
World J Clin Cases; 2020 Oct; 8(20):4700-4707. PubMed ID: 33195637
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
[TBL] [Abstract][Full Text] [Related]
12. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
Matsumoto K; Ikawa K; Abematsu K; Fukunaga N; Nishida K; Fukamizu T; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
Int J Antimicrob Agents; 2009 Jul; 34(1):91-4. PubMed ID: 19261446
[TBL] [Abstract][Full Text] [Related]
13. [CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].
Qu HL; Guo DD; Xu T; Li Z; Yin J; Tian XP; Kong DQ; Zhu XM; Miao LY; Wu DP; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):202-206. PubMed ID: 29562464
[No Abstract] [Full Text] [Related]
14. Voriconazole-Induced Hepatotoxicity in a Patient with Pulmonary Aspergillosis: A Case Report.
Gu L; Ai T; Pang L; Xu D; Wang H
Infect Drug Resist; 2023; 16():5405-5411. PubMed ID: 37614681
[TBL] [Abstract][Full Text] [Related]
15. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
[TBL] [Abstract][Full Text] [Related]
16. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis.
Hanai Y; Hamada Y; Kimura T; Matsumoto K; Takahashi Y; Fujii S; Nishizawa K; Takesue Y
J Infect Chemother; 2021 Feb; 27(2):151-160. PubMed ID: 33376032
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
[TBL] [Abstract][Full Text] [Related]
18. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
[TBL] [Abstract][Full Text] [Related]
20. [Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration].
Xue S; Lu H; Tang L; Fang J; Shi L; Li J; Yu Y; Zhou Q; Xue S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jan; 32(1):50-55. PubMed ID: 32148231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
